Form 4 Filing for Celldex Therapeutics, Inc.

Rita Jain, a director at Celldex Therapeutics, Inc. (CLDX), was granted 26,000 non-qualified stock options on June 25, 2026. These options, granted under the company's 2021 Omnibus Equity Incentive Plan, have an exercise price of $34.09 and are exercisable until June 25, 2036. The options were granted with a transaction code "A" for acquisition and have a post-transaction ownership of 26,000 shares. The underlying security is Common Stock. The filing is dated June 29, 2026.